Comparing the current results to its competitors, Monte Rosa Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -95.04 %, despite the revenue increase by the most of its competitors of 4.97 %, recorded in the same quarter.
Monte Rosa Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 3.5 %
September 15, 2025
Monte Rosa Therapeutics Collaborates with Novartis Amid Significant Revenue Growth and Market ChallengesMonte Rosa Therapeutics Inc. has recently announced a collaboration with Novartis to develop targeted degraders aimed at treating immune-mediated diseases. This partnership is expected to leverage both companies’ expertise in drug development to enhance treatment options for patients suffering from these complex conditions.As Monte Rosa Therapeutics charts its path in biotechnology, the company s financial performance in the second quarter of 2025 reveals a significant upward trend. According to the company’s statements, it recorded an impressive year-on-year revenue increase of 394.01%. This growth s...
December 11, 2024
In the rapidly evolving landscape of oncology therapeutics, the innovations brought forth by Monte Rosa Therapeutics present a notable advancement in the targeted treatment of breast cancer and potentially other diseases. Recent presentations at prestigious medical conferences highlight promising preclinical data regarding the company’s CDK2-directed molecular glue degraders, particularly MRT-2359 and MRT-6160. This article interprets their findings at the 2024 San Antonio Breast Cancer Symposium and Digestive Disease Week 2024, assessing their potential implications for patients and the company’s forward momentum. 1. Emerging Treatments for Breast Cancer At the 2024 San Antonio Breast Cancer Symposium, ...
June 27, 2024
Monte Rosa Therapeutics, a leading biotechnology company, has recently provided updates on the development progress of three promising therapeutic candidates: MRT-2359, MRT-6160, and MRT-8102. These advancements demonstrate the company s commitment to addressing unmet medical needs using innovative approaches such as molecular glues and pathway inhibitors. This article aims to summarize the key findings from the provided articles and shed light on the potential of these novel therapies.Development Progress Updates on MRT-2359 and MRT-6160: According to the article Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160, Monte Rosa Therapeutics has disclosed significant milesto...
Twist Bioscience Corporation operates as a biotechnology company that focuses on synthetic DNA manufacturing. Its business model consists of providing customers with custom DNA synthesis, gene libraries, and specialty components. This includes offering a variety of products and services tailored to meet the specific needs of researchers and biotech companies, enabling them to accelerate their development of personalized medicines, agricultural biotechnology, and more.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Inhibrx Inc operates using a business model that focuses on the development and commercialization of therapeutics. The company leverages its innovative technology platform to create a diverse pipeline of biologics for the treatment of various diseases. Inhibrx Inc aims to collaborate with strategic partners to advance the development of its pipeline and expand its reach in the healthcare market.
Sources:
Monte Rosa Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Monte Rosa Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
